Brickell Selling General and Administrative Expense Trend from 2010 to 2022

BBI
 Stock
  

USD 3.36  0.09  2.75%   

Brickell Biotech Selling General and Administrative Expense is increasing over the last several years with stable swings. Selling General and Administrative Expense is predicted to flatten to about 12.1 M. During the period from 2010 to 2022 Brickell Biotech Selling General and Administrative Expense regressed destribution of quarterly values had coefficient of variationof 22.60 and r-squared of  0.06. Brickell Biotech Gross Profit is most likely to decrease significantly in the upcoming years. The last year's value of Gross Profit was reported at 404,000. The current Interest Expense is estimated to increase to about 63.7 K, while Consolidated Income is projected to decrease to (40.5 M).
  
Check Brickell Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brickell main balance sheet or income statement drivers, such as Direct Expenses of 1.7 M, Cost of Revenue of 7.3 M or Gross Profit of 414.6 K, as well as many exotic indicators such as PPandE Turnover of 4.69, Accounts Payable Turnover of 2.36 or Accrued Expenses Turnover of 0.54. Brickell financial statements analysis is a perfect complement when working with Brickell Biotech Valuation or Volatility modules. It can also supplement various Brickell Biotech Technical models . Continue to the analysis of Brickell Biotech Correlation against competitors.

Brickell Biotech Quarterly Selling General and Administrative Expense

3.91 Million

Brickell Selling General and Administrative Expense Breakdown

Showing smoothed Selling General and Administrative Expense of Brickell Biotech with missing and latest data points interpolated. A component of Operating Expenses representing the aggregate total costs related to selling a firm's product and services; as well as all other general and administrative expenses. Direct selling expenses (for example; credit; warranty; and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products; for example telephone expenses; Internet; and postal charges. General and administrative expenses include salaries of non-sales personnel; rent; utilities; communication; etc.Brickell Biotech's Selling General and Administrative Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Brickell Biotech's overall financial position and show how it may be relating to other accounts over time.
Selling General and Administrative Expense10 Years Trend
Increasing
Stable
   Selling General and Administrative Expense   
Share
       Timeline  

Brickell Selling General and Administrative Expense Regression Statistics

Arithmetic Mean 9,810,494
Geometric Mean 9,557,447
Coefficient Of Variation 22.60
Mean Deviation 1,812,840
Median 9,598,000
Standard Deviation 2,217,247
Range 6,082,000
R-Value 0.25
R-Squared 0.06
Significance 0.41
Slope 142,492

Brickell Selling General and Administrative Expense History

201210.6 M
201311.8 M
20149.6 M
20158.4 M
20167.1 M
20176.3 M
20186.4 M
201912.2 M
202011.6 M
202112.4 M
202212.1 M

About Brickell Biotech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Brickell Biotech income statement, its balance sheet, and the statement of cash flows. Brickell Biotech investors use historical funamental indicators, such as Brickell Biotech's Selling General and Administrative Expense, to determine how well the company is positioned to perform in the future. Although Brickell Biotech investors may use each financial statement separately, they are all related. The changes in Brickell Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brickell Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Brickell Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Brickell Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Selling General and Administrative Expense12.4 M12.1 M
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brickell Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Piotroski F Score Now

   

Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
All  Next Launch Module

Pair Trading with Brickell Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving together with Brickell Biotech

0.87ABVCAbvc Biopharma Earnings Call  This WeekPairCorr
0.66AGTCApplied Genetic Tech Fiscal Year End 22nd of September 2022 PairCorr

Moving against Brickell Biotech

0.91AGLAgilon Health Downward RallyPairCorr
0.87ADVMAdverum Biotechnlgs Earnings Call  This WeekPairCorr
0.81AVXLAnavex Lf SC Fiscal Year End 23rd of November 2022 PairCorr
0.79ARWRArrowhead Pharma Fiscal Year End 28th of November 2022 PairCorr
The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Brickell Biotech Correlation against competitors. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
8.8 M
Quarterly Revenue Growth YOY
4.41
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.